Previous Close | 31.65 |
Open | 32.75 |
Bid | 0.00 x 800 |
Ask | 0.00 x 2200 |
Day's Range | 32.75 - 33.54 |
52 Week Range | 21.69 - 73.40 |
Volume | |
Avg. Volume | 8,522 |
Net Assets | 10.42M |
NAV | 33.41 |
PE Ratio (TTM) | N/A |
Yield | 0.00% |
YTD Daily Total Return | -26.70% |
Beta (5Y Monthly) | 0.77 |
Expense Ratio (net) | 0.95% |
Inception Date | 2009-06-04 |
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and update at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:00 a.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see XP Power...